Document Format Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
1 | ANNUAL REPORT | f20f2022_universe.htm iXBRL | 20-F | 2412483 |
2 | DESCRIPTION OF SECURITIES | f20f2022ex2-3_universe.htm | EX-2.3 | 94267 |
3 | ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BET | f20f2022ex4-11_universe.htm | EX-4.11 | 117812 |
4 | ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BET | f20f2022ex4-12_universe.htm | EX-4.12 | 149642 |
5 | ENGLISH TRANSLATION OF THE WORKING CAPITAL LOAN CONTRACT ENTERED INTO BY AND BET | f20f2022ex4-13_universe.htm | EX-4.13 | 187350 |
6 | ENGLISH TRANSLATION OF THE LETTER OF INTENT ON TRANSFER OF EQUITY INTERESTS IN Y | f20f2022ex4-14_universe.htm | EX-4.14 | 34326 |
7 | CERTIFICATION | f20f2022ex12-1_universe.htm | EX-12.1 | 7390 |
8 | CERTIFICATION | f20f2022ex12-2_universe.htm | EX-12.2 | 7336 |
9 | CERTIFICATION | f20f2022ex13-1_universe.htm | EX-13.1 | 3421 |
10 | CERTIFICATION | f20f2022ex13-2_universe.htm | EX-13.2 | 3421 |
11 | CONSENT OF ALLBRIGHT LAW OFFICES (FUZHOU) | f20f2022ex15-1_universe.htm | EX-15.1 | 5113 |
12 | CONSENT OF YCM CPA INC | f20f2022ex15-2_universe.htm | EX-15.2 | 2688 |
13 | CONSENT OF FRIEDMAN LLP | f20f2022ex15-3_universe.htm | EX-15.3 | 2159 |
14 | GRAPHIC | img_001.jpg | GRAPHIC | 72283 |
15 | GRAPHIC | img_002.jpg | GRAPHIC | 71723 |
16 | GRAPHIC | img_003.jpg | GRAPHIC | 7423 |
17 | GRAPHIC | img_004.jpg | GRAPHIC | 6210 |
18 | GRAPHIC | ex4-11_001.jpg | GRAPHIC | 1656 |
19 | GRAPHIC | ex4-11_002.jpg | GRAPHIC | 1639 |
20 | GRAPHIC | ex4-11_003.jpg | GRAPHIC | 50422 |
21 | GRAPHIC | ex4-11_004.jpg | GRAPHIC | 3631 |
22 | GRAPHIC | ex4-11_005.jpg | GRAPHIC | 9833 |
23 | GRAPHIC | ex4-11_006.jpg | GRAPHIC | 8381 |
24 | GRAPHIC | ex4-11_007.jpg | GRAPHIC | 13166 |
25 | GRAPHIC | ex4-12_001.jpg | GRAPHIC | 971 |
26 | GRAPHIC | ex4-12_002.jpg | GRAPHIC | 1424 |
27 | GRAPHIC | ex4-12_003.jpg | GRAPHIC | 1462 |
28 | GRAPHIC | ex4-12_004.jpg | GRAPHIC | 1449 |
29 | GRAPHIC | ex4-12_005.jpg | GRAPHIC | 1475 |
30 | GRAPHIC | ex4-12_006.jpg | GRAPHIC | 1446 |
31 | GRAPHIC | ex4-12_007.jpg | GRAPHIC | 1441 |
32 | GRAPHIC | ex4-12_008.jpg | GRAPHIC | 1430 |
33 | GRAPHIC | ex4-12_009.jpg | GRAPHIC | 4115 |
34 | GRAPHIC | ex4-12_010.jpg | GRAPHIC | 1343 |
35 | GRAPHIC | ex4-12_011.jpg | GRAPHIC | 2634 |
36 | GRAPHIC | ex4-12_012.jpg | GRAPHIC | 1617 |
37 | GRAPHIC | ex4-12_013.jpg | GRAPHIC | 2730 |
38 | GRAPHIC | ex4-12_014.jpg | GRAPHIC | 6924 |
39 | GRAPHIC | ex4-12_015.jpg | GRAPHIC | 4477 |
40 | GRAPHIC | ex4-12_016.jpg | GRAPHIC | 6607 |
41 | GRAPHIC | ex4-13_001.jpg | GRAPHIC | 19479 |
42 | GRAPHIC | ex4-13_002.jpg | GRAPHIC | 21140 |
43 | GRAPHIC | ex4-13_003.jpg | GRAPHIC | 8406 |
44 | GRAPHIC | ex4-14_001.jpg | GRAPHIC | 5610 |
45 | GRAPHIC | ex4-14_002.jpg | GRAPHIC | 5616 |
46 | GRAPHIC | ex4-14_003.jpg | GRAPHIC | 2740 |
47 | GRAPHIC | ex4-14_004.jpg | GRAPHIC | 3030 |
48 | GRAPHIC | ex4-14_005.jpg | GRAPHIC | 5337 |
49 | GRAPHIC | ex15-1_001.jpg | GRAPHIC | 130457 |
50 | GRAPHIC | ex15-1_002.jpg | GRAPHIC | 43249 |
51 | GRAPHIC | ex15-3_001.jpg | GRAPHIC | 8087 |
57 | GRAPHIC | ex15-2_001.jpg | GRAPHIC | 5147 |
Complete submission text file | 0001213900-23-010349.txt | 10138278 |
Data Files
Seq | Description | Document | Type | Size |
---|---|---|---|---|
52 | XBRL SCHEMA FILE | upc-20220930.xsd | EX-101.SCH | 105209 |
53 | XBRL CALCULATION FILE | upc-20220930_cal.xml | EX-101.CAL | 45422 |
54 | XBRL DEFINITION FILE | upc-20220930_def.xml | EX-101.DEF | 357772 |
55 | XBRL LABEL FILE | upc-20220930_lab.xml | EX-101.LAB | 675379 |
56 | XBRL PRESENTATION FILE | upc-20220930_pre.xml | EX-101.PRE | 373637 |
148 | EXTRACTED XBRL INSTANCE DOCUMENT | f20f2022_universe_htm.xml | XML | 805242 |
IRS No.: 000000000 | State of Incorp.: F4 | Fiscal Year End: 0930
Type: 20-F | Act: 34 | File No.: 001-40231 | Film No.: 23613073
SIC: 2834 Pharmaceutical Preparations